Business Context and Reporting Period
Company: NewGenIvf Group Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2025
Date of Filing: June 20, 2025
This filing serves as an update regarding the company's capital structure and outstanding share count as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity capitalization changes.
Material Changes
The most significant change disclosed is a substantial increase in the total issued and outstanding shares:
- Current Total Shares: 4,324,565
- Prior Total Shares (per June 3, 2025 Prospectus): 1,050,840
- Share Composition: 4,304,037 Class A ordinary shares and 20,528 Class B ordinary shares.
Drivers of Increase:
- Exercises of warrants and convertible notes by an existing holder.
- Share issuances pursuant to the Common Shares Purchase Agreement with White Lion Capital, LLC.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operations, specific risks, contingencies, or unusual items beyond the capitalization update.
Investor Verification Checklist
- Verify the exact terms and pricing of the Common Shares Purchase Agreement with White Lion Capital, LLC.
- Confirm the conversion rates and exercise prices for the warrants and convertible notes that were exercised.
- Review the June 3, 2025 prospectus to compare the original capitalization structure against the current state.
- Assess the dilution impact on existing shareholders resulting from the tripling of the share count.